Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders

Neurobiology of Disease

Volumn 85, Issue , 2016, Pages 254-261

  Verkhratsky, Alexei ^a,b,e   Parpura, Vladimir ^c,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BASQUE FOUNDATION FOR SCIENCE   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e University of Rijeka   (Croatia)

Author keywords

Astrocyte; Hepatic encephalopathy; Neurodegeneration; Neuroglia; Neurological diseases; Psychiatric diseases; Reactive astrogliosis

Indexed keywords

ADDICTION; ALEXANDER DISEASE; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTROCYTE; BRAIN DISEASE; BRAIN TOXICITY; CELL FUNCTION; CEREBROVASCULAR ACCIDENT; DEPRESSION; HUMAN; HUNTINGTON CHOREA; HYPERAMMONEMIA ENCEPHALOPATHY; KORSAKOFF PSYCHOSIS; MAJOR DEPRESSION; MENTAL DISEASE; NERVOUS SYSTEM INJURY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SCHIZOPHRENIA; WERNICKE ENCEPHALOPATHY; ANIMAL; BRAIN; DEGENERATIVE DISEASE; GROWTH, DEVELOPMENT AND AGING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ASTROCYTES; BRAIN; HUMANS; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; NEURODEVELOPMENTAL DISORDERS;

EID: 84949727759     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.03.025     Document Type: Article

References (157)

1. 2+-dependent endoplasmic reticulum stress correlates with astrogliosis in oligomeric amyloid β-treated astrocytes and in a model of Alzheimer's disease. Aging Cell 2013, 12:292-302.
2. Albrecht J., et al. Glutamine as a mediator of ammonia neurotoxicity: a critical appraisal. Biochem. Pharmacol. 2010, 80:1303-1308.
3. Alexander W.S. Progressive fibrinoid degeneration of fibrillary astrocytes associated with mental retardation in a hydrocephalic infant. Brain 1949, 72:373-381.
4. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psychol. Gerichtl. Med. 1907, 64:146-148.
5. Armstrong V., et al. Repeated amphetamine treatment causes a persistent elevation of glial fibrillary acidic protein in the caudate-putamen. Eur. J. Pharmacol. 2004, 488:111-115.
6. Barley K., et al. Subcortical oligodendrocyte- and astrocyte-associated gene expression in subjects with schizophrenia, major depression and bipolar disorder. Schizophr. Res. 2009, 112:54-64.
7. Barres B.A. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 2008, 60:430-440.
8. Beauquis J., et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease. Exp. Neurol. 2013, 239:28-37.
9. Beauquis J., et al. Neuronal and glial alterations, increased anxiety, and cognitive impairment before hippocampal amyloid deposition in PDAPP mice, model of Alzheimer's disease. Hippocampus 2014, 24:257-269.
10. Behrens P.F., et al. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 2002, 125:1908-1922.
11. Bendikov I., et al. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr. Res. 2007, 90:41-51.
12. Bernard R., et al. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol. Psychiatry 2011, 16:634-646.
13. Bernstein H., et al. Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy. Schizophr. Res. 2015, 161:4-18.
14. Beschorner R., Dietz K., Schauer N., Mittelbronn M., Schluesener H.J., Trautmann K., Meyermann R., Simon P. Expression of EAAT1 reflects a possible neuroprotective function of reactive astrocytes and activated microglia following human traumatic brain injury. Histol. Histopathol. 2007, 22:515-526.
15. Braak H., et al. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog. Brain Res. 1998, 117:267-285.
16. Braun K., et al. Juvenile separation stress induces rapid region- and layer-specific changes in S100ss- and glial fibrillary acidic protein-immunoreactivity in astrocytes of the rodent medial prefrontal cortex. Neuroscience 2009, 160:629-638.
17. Brusilow S.W., et al. Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy. Neurotherapeutics 2010, 7:452-470.
18. Burda J.E., Sofroniew M.V. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 2014, 81:229-248.
19. Butterworth R.F. Hepatic encephalopathy: a central neuroinflammatory disorder?. Hepatology 2011, 53:1372-1376.
20. Büttner A., Weis S. Neuropathological alterations in drug abusers. The involvement of neurons, glial and vascular systems. Forensic Sci. Med. Pathol. 2006, 2:115-126.
21. Chen C., et al. Role of astroglia in Down's syndrome revealed by patient-derived human-induced pluripotent stem cells. Nat. Commun. 2014, 5:4430.
22. Clarke L.E., Barres B.A. Emerging roles of astrocytes in neural circuit development. Nat. Rev. Neurosci. 2013, 14:311-321.
23. Cullen K.M., Halliday G.M. Chronic alcoholics have substantial glial pathology in the forebrain and diencephalon. Alcohol Alcohol. Suppl. 1994, 2:253-257.
24. Czeh B., et al. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 2006, 31:1616-1626.
25. Ede R.J., Williams R.W. Hepatic encephalopathy and cerebral edema. Semin. Liver Dis. 1986, 6:107-118.
26. Faideau M., et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum. Mol. Genet. 2010, 19:3053-3067.
27. Fatemi S.H., et al. Expression of astrocytic markers aquaporin 4 and connexin 43 is altered in brains of subjects with autism. Synapse 2008, 62:501-507.
28. Fatemi S.H., et al. Viral regulation of aquaporin 4, connexin 43, microcephalin and nucleolin. Schizophr. Res. 2008, 98:163-177.
29. Fattore L., et al. Astroglial in vivo response to cocaine in mouse dentate gyrus: a quantitative and qualitative analysis by confocal microscopy. Neuroscience 2002, 110:1-6.
30. Felipo V. Hepatic encephalopathy: effects of liver failure on brain function. Nat. Rev. Neurosci. 2013, 14:851-858.
31. Fuller S., et al. Activated astrocytes: a therapeutic target in Alzheimer's disease?. Expert. Rev. Neurother. 2009, 9:1585-1594.
32. Glees P. Neuroglia Morphology and Function 1955, Blackwell, Oxford.
33. Gray M., et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 2008, 28:6182-6195.
34. Grolla A.A., et al. Amyloid-β and Alzheimer's disease type pathology differentially affects the calcium signaling toolkit in astrocytes from different brain regions. Cell Death Dis. 2013, 4. (e623).
35. Guidetti P., et al. Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia 2007, 55:78-92.
36. Haack N., et al. Dysbalance of astrocyte calcium under hyperammonemic conditions. PLoS ONE 2014, 9:e105832.
37. Hassel B., et al. Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem. Res. 2008, 33:232-237.
38. Hazell A.S. Astrocytes are a major target in thiamine deficiency and Wernicke's encephalopathy. Neurochem. Int. 2009, 55:129-135.
39. Hazell A.S., et al. Loss of astrocytic glutamate transporters in Wernicke encephalopathy. Glia 2009, 58:148-156.
40. Heneka M.T., et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J. Neuroinflammation 2005, 2:22.
41. Hercher C., et al. Through the looking glass: examining neuroanatomical evidence for cellular alterations in major depression. J. Psychiatr. Res. 2009, 43:947-961.
42. Huntington G. On chorea. Med. Surg. Rep. Phila. 1872, 26:317-321.
43. Iadecola C., Nedergaard M. Glial regulation of the cerebral microvasculature. Nat. Neurosci. 2007, 10:1369-1376.
44. Jacobs S., Doering L.C. Astrocytes prevent abnormal neuronal development in the fragile x mouse. J. Neurosci. 2010, 30:4508-4514.
45. Jacobs S., et al. Fragile X astrocytes induce developmental delays in dendrite maturation and synaptic protein expression. BMC Neurosci. 2010, 11:132.
46. Jayakumar A.R., et al. Decreased astrocytic thrombospondin-1 secretion after chronic ammonia treatment reduces the level of synaptic proteins: in vitro and in vivo studies. J. Neurochem. 2014, 131:333-347.
47. Kanemaru K., et al. Calcium-dependent N-cadherin up-regulation mediates reactive astrogliosis and neuroprotection after brain injury. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:11612-11617.
48. Karlsen A.S., Pakkenberg B. Total numbers of neurons and glial cells in cortex and basal ganglia of aged brains with Down syndrome-a stereological study. Cereb. Cortex 2011, 21:2519-2524.
49. Kelly T., Rose C.R. Ammonium influx pathways into astrocytes and neurons of hippocampal slices. J. Neurochem. 2010, 115:1123-1136.
50. Kelly T., et al. Ammonium-evoked alterations in intracellular sodium and pH reduce glial glutamate transport activity. Glia 2009, 57:921-934.
51. Neuroglia 2013, Oxford University Press, Oxford. H. Kettenmann, B.R. Ransom (Eds.).
52. Kettenmann H., Verkhratsky A. Neuroglia: the 150years after. Trends Neurosci. 2008, 31:653-659.
53. Kimelberg H.K., Nedergaard M. Functions of astrocytes and their potential as therapeutic targets. Neurotherapeutics 2010, 7:338-353.
54. Kondziella D., et al. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?. Neurochem. Int. 2007, 50:291-301.
55. Korsakoff,[English translation available in Victor, M., and Yakovlev, P.I. 1995. S.S. Korsakoff's psychic disorder in conjunction with peripheral neuritis; a translation of Korsakoff's original article with brief comments on the author and his contribution to clinical medicine. Neurology. 5:394-406].
56. Kraepelin E. Psychiatrie: Ein Lehrbuch fur Studierende und Arzte 1910, Barth, Leipzig. 8th ed.
57. Kreft M., et al. Aspects of astrocyte energy metabolism, amino acid neurotransmitter homoeostasis and metabolic compartmentation. ASN Neuro 2012, 4.
58. Kriegstein A., Alvarez-Buylla A. The glial nature of embryonic and adult neural stem cells. Annu. Rev. Neurosci. 2009, 32:149-184.
59. Kulijewicz-Nawrot M., et al. Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer's disease. J. Anat. 2012, 221:252-262.
60. Labrie V., et al. Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum. Mol. Genet. 2009, 18:3227-3243.
61. Laird M.D., Vender J.R., Dhandapani K.M. Opposing roles for reactive astrocytes following traumatic brain injury. Neurosignals 2008, 16:154-164. (Epub 2008 Feb 5). 10.1159/000111560.
62. Laruelle M. Schizophrenia: from dopaminergic to glutamatergic interventions. Curr. Opin. Pharmacol. 2014, 14:97-102.
63. 2+-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse model. Neurobiol. Dis. 2013, 58:192-199.
64. 2+ signaling and up-regulates expression of TRPC1 gene in astrocytes in primary cultures and in the in vivo brain. Neurochem. Res. 2014, 39:2127-2135.
65. Lievens J.C., et al. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol. Dis. 2001, 8:807-821.
66. Lim D., et al. Glial calcium signaling in Alzheimer's disease. Rev. Physiol. Biochem. Pharmacol. 2014, 167:45-65.
67. Lin J.H., et al. Gap-junction-mediated propagation and amplification of cell injury. Nat. Neurosci. 1998, 1:494-500.
68. Link A., et al. 21-year-old woman with Reye's syndrome after influenza. Dtsch. Med. Wochenschr. 2012, 137:1853-1856.
69. Ma T.M., et al. Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion. Mol. Psychiatry 2013, 18:557-567.
70. Maier K., et al. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol. Dis. 2007, 25:514-525.
71. Martineau M., et al. Cell-type specific mechanisms of D-serine uptake and release in the brain. Front Synaptic Neurosci. 2014, 6:12.
72. Messing A., et al. Strategies for treatment in Alexander disease. Neurotherapeutics 2010, 7:507-515.
73. Messing A., et al. Alexander disease. J. Neurosci. 2012, 32:5017-5023.
74. Miguel-Hidalgo J.J. Lower packing density of glial fibrillary acidic protein-immunoreactive astrocytes in the prelimbic cortex of alcohol-naive and alcohol-drinking alcohol-preferring rats as compared with alcohol-nonpreferring and Wistar rats. Alcohol. Clin. Exp. Res. 2005, 29:766-772.
75. Miguel-Hidalgo J.J. The role of glial cells in drug abuse. Curr. Drug Abuse Rev. 2009, 2:76-82.
76. Miguel-Hidalgo J.J., et al. Glia pathology in the prefrontal cortex in alcohol dependence with and without depressive symptoms. Biol. Psychiatry 2002, 52:1121-1133.
77. Miguel-Hidalgo J.J., et al. Reduced glial and neuronal packing density in the orbitofrontal cortex in alcohol dependence and its relationship with suicide and duration of alcohol dependence. Alcohol. Clin. Exp. Res. 2006, 30:1845-1855.
78. Molofsky A.V., et al. Astrocytes and disease: a neurodevelopmental perspective. Genes Dev. 2012, 26:891-907.
79. Montana V., et al. Pathological role for exocytotic glutamate release from astrocytes in hepatic encephalopathy. Curr. Neuropharmacol. 2014, 12:324-333.
80. Moussawi K., et al. Extracellular glutamate: functional compartments operate in different concentration ranges. Front. Syst. Neurosci. 2011, 5:94.
81. Muller N., Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res. 2006, 10:131-148.
82. Nedergaard M., Verkhratsky A. Artifact versus reality-how astrocytes contribute to synaptic events. Glia 2012, 60:1013-1023.
83. Nedergaard M., et al. Glial calcium and diseases of the nervous system. Cell Calcium 2010, 47:140-149.
84. Norenberg M.D. The role of astrocytes in hepatic encephalopathy. Neurochem. Pathol. 1987, 6:13-33.
85. Obara-Michlewska M., et al. Astroglial NMDA receptors inhibit expression of K4.1 channels in glutamate-overexposed astrocytes in vitro and in the brain of rats with acute liver failure. Neurochem. Int. 2014, (E-pub ahead of print). 10.1016/j.neuint.2014.10.006.
86. Oberheim N.A., et al. Heterogeneity of astrocytic form and function. Methods Mol. Biol. 2012, 814:23-45.
87. Oehmichen M., et al. Neuropathology in non-human immunodeficiency virus-infected drug addicts: hypoxic brain damage after chronic intravenous drug abuse. Acta Neuropathol. 1996, 91:642-646.
88. Olabarria M., et al. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia 2010, 58:831-838.
89. Parpura V., et al. Glial cells in (patho)physiology. J. Neurochem. 2012, 121:4-27.
90. Pekna M., Pekny M. The neurobiology of brain injury. Cerebrum. 2012, 2012:9.
91. Pekny M., Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005, 50:427-434.
92. Pekny M., et al. The dual role of astrocyte activation and reactive gliosis. Neurosci. Lett. 2014, 565:30-38.
93. Quaak I., et al. The dynamics of autism spectrum disorders: how neurotoxic compounds and neurotransmitters interact. Int. J. Environ. Res. Public Health 2013, 10:3384-3408.
94. Rajkowska G., Stockmeier C.A. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr. Drug Targets 2013, 14:1225-1436.
95. Rajkowska G., et al. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch. Gen. Psychiatry 1998, 55:215-224.
96. Rajkowska G., et al. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr. Res. 2002, 57:127-138.
97. Rama Rao K.V., Norenberg M.D. Glutamine in the pathogenesis of hepatic encephalopathy: the trojan horse hypothesis revisited. Neurochem. Res. 2014, 39:593-598.
98. Rama Rao K.V., et al. Brain edema in acute liver failure: mechanisms and concepts. Metab. Brain Dis. 2014, 29:927-936.
99. Rangroo Thrane V., et al. Ammonia triggers neuronal disinhibition and seizures by impairing astrocyte potassium buffering. Nat. Med. 2013, 19:1643-1648.
100. Rao V.L., Başkaya M.K., Doğan A., Rothstein J.D., Dempsey R.J. Traumatic brain injury down-regulates glial glutamate transporter (GLT-1 and GLAST) proteins in rat brain. J. Neurochem. 1998, 70:2020-2027.
101. Robel S., et al. The stem cell potential of glia: lessons from reactive gliosis. Nat. Rev. Neurosci. 2011, 12:88-104.
102. Rodriguez J.J., Verkhratsky A. Neuroglial roots of neurodegenerative diseases?. Mol. Neurobiol. 2011, 43:87-96.
103. Rose C.F., et al. Astrocyte glutamine synthetase: pivotal in health and disease. Biochem. Soc. Trans. 2013, 41:1518-1524.
104. Rossi D., Volterra A. Astrocytic dysfunction: insights on the role in neurodegeneration. Brain Res. Bull. 2009, 80:224-232.
105. Rossi D., et al. Focal degeneration of astrocytes in amyotrophic lateral sclerosis. Cell Death Differ. 2008, 15:1691-1700.
106. Rubinov M., Bullmore E. Schizophrenia and abnormal brain network hubs. Dialogues Clin. Neurosci. 2013, 15:339-349.
107. Sanacora G., Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol. Psychiatry 2013, 73:1172-1179.
108. Schmitt A., et al. Schizophrenia as a disorder of disconnectivity. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261(Suppl. 2):S150-S154.
109. Schnieder T.P., Dwork A.J. Searching for neuropathology: gliosis in schizophrenia. Biol. Psychiatry 2011, 69:134-139.
110. Schwarcz R., Hunter C.A. Toxoplasma gondii and schizophrenia: linkage through astrocyte-derived kynurenic acid?. Schizophr. Bull. 2007, 33:652-653.
111. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
112. Sequeira A., et al. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS ONE 2009, 4:e6585.
113. Neurobiology of Hyperthermia 2011, 591. Elsevier, Amsterdam. H.S. Sharma (Ed.).
114. Shin J.Y., et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 2005, 171:1001-1012.
115. Singhrao S.K., et al. Huntingtin protein colocalizes with lesions of neurodegenerative diseases: an investigation in Huntington's, Alzheimer's, and Pick's diseases. Exp. Neurol. 1998, 150:213-222.
116. Skuja S., et al. Alcoholism and cellular vulnerability in different brain regions. Ultrastruct. Pathol. 2012, 36:40-47.
117. Sofroniew M.V. Reactive astrocytes in neural repair and protection. Neuroscientist 2005, 11:400-407.
118. Sofroniew M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009, 32:638-647.
119. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathol. 2010, 119:7-35.
120. Song W., et al. Schizophrenia-like features in transgenic mice overexpressing human HO-1 in the astrocytic compartment. J. Neurosci. 2012, 32:10841-10853.
121. Spangaro M., et al. Cognitive dysfunction and glutamate reuptake: effect of EAAT2 polymorphism in schizophrenia. Neurosci. Lett. 2012, 522:151-155.
122. Staats K.A., Van Den Bosch L. Astrocytes in amyotrophic lateral sclerosis: direct effects on motor neuron survival. J. Biol. Phys. 2009, 35:337-346.
123. Struys-Ponsar C., et al. Effects of aluminum exposure on glutamate metabolism: a possible explanation for its toxicity. Exp. Neurol. 2000, 163:157-164.
124. Suarez I., et al. Neuronal and astroglial response to pre- and perinatal exposure to delta-9-tetra- hydrocannabinol in the rat substantia nigra. Dev. Neurosci. 2000, 22:253-263.
125. Suarez-Fernandez M.B., et al. Aluminum-induced degeneration of astrocytes occurs via apoptosis and results in neuronal death. Brain Res. 1999, 835:125-136.
126. Takahashi N., Sakurai T. Roles of glial cells in schizophrenia: possible targets for therapeutic approaches. Neurobiol. Dis. 2013, 53:49-60.
127. Takano T., et al. Astrocytes and ischemic injury. Stroke 2009, 40:S8-S12.
128. Tanaka J., et al. Astrocytes prevent neuronal death induced by reactive oxygen and nitrogen species. Glia 1999, 28:85-96.
129. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
130. Thrane A.S., et al. Drowning stars: reassessing the role of astrocytes in brain edema. Trends Neurosci. 2014, 37:620-628.
131. ir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nat. Neurosci. 2014, 17:694-703.
132. Valori C.F., et al. The multifaceted role of glial cells in amyotrophic lateral sclerosis. Cell. Mol. Life Sci. 2014, 71:287-297.
133. Verkhratsky A. Neuronismo y reticulismo: neuronal-glial circuits unify the reticular and neuronal theories of brain organization. Acta Physiol. (Oxf.) 2009, 195:111-122.
134. Verkhratsky A. Physiology of neuronal-glial networking. Neurochem. Int. 2010, 57:332-343.
135. Verkhratsky A., Butt A.M. Glial Physiology and Pathophysiology 2013, Wiley-Blackwell, Chichester.
136. Verkhratsky A., et al. Astrocytes in Alzheimer's disease. Neurotherapeutics 2010, 7:399-412.
137. Verkhratsky A., et al. Neurological diseases as primary gliopathies: a reassessment of neurocentrism. ASN Neuro 2012, 4.
138. Verkhratsky A., et al. Astroglia in neurological diseases. Future Neurol. 2013, 8:149-158.
139. Verkhratsky A., et al. Glia in the pathogenesis of neurodegenerative diseases. Biochem. Soc. Trans. 2014, 42:1291-1301.
140. Verkhratsky A., et al. Neuroglia in ageing and disease. Cell Tissue Res. 2014, 357:493-503.
141. Verkhratsky A., et al. Astrogliopathology: a central element of neuropsychiatric diseases?. Neuroscientist 2014, 20:576-588.
142. Verkhratsky A., et al. Glial asthenia and functional paralysis: a new perspective on neurodegeneration and Alzheimer's disease. Neuroscientist 2014, 10.1177/1073858414547132.
143. Wang L., et al. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum. Mol. Genet. 2011, 20:286-293.
144. Weber M., et al. Quantitative analysis of astrogliosis in drug-dependent humans. Brain Res. 2013, 1500:72-87.
145. Wernicke C. Lehrbuch der Gehirnkrankheiten für Aerzte und Studirende 1881-1883, Theodor Fischer, Kassel und Berlin.
146. Williams M.R., et al. Astrocyte decrease in the subgenual cingulate and callosal genu in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263:41-52.
147. Wilson E.H., Hunter C.A. The role of astrocytes in the immunopathogenesis of toxoplasmic encephalitis. Int. J. Parasitol. 2004, 34:543-548.
148. Wisniewski K.E., et al. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 1985, 17:278-282.
149. Xia M., et al. Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia. Schizophr. Res. 2014, 10.1016/j.schres.2014.10.044.
150. Yamanaka K., et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008, 11:251-253.
151. Yeh C.Y., et al. Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer's disease. ASN Neuro 2011, 3:271-279.
152. Yin Z., et al. Methylmercury induces oxidative injury, alterations in permeability and glutamine transport in cultured astrocytes. Brain Res. 2007, 1131:1-10.
153. Yoshida T., et al. Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis. J. Neurol. 2011, 258:1998-2008.
154. Zeidan-Chulia F., et al. The glial perspective of autism spectrum disorders. Neurosci. Biobehav. Rev. 2014, 38:160-172.
155. Zhang Y., Barres B.A. Astrocyte heterogeneity: an underappreciated topic in neurobiology. Curr. Opin. Neurobiol. 2010, 20:588-594.
156. Zhao Y., Rempe D.A. Targeting astrocytes for stroke therapy. Neurotherapeutics 2010, 7:439-451.
157. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 2000, 23:217-247.